| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/30/2013 | CA2856411A1 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| 05/29/2013 | EP2597105A1 A conjugate comprising angiostatin or its fragment, the method for producing the conjugate and use thereof |
| 05/29/2013 | EP2596813A1 Sheet preparation for tissue adhesion |
| 05/29/2013 | EP2596805A1 Prodrug comprising a drug linker conjugate |
| 05/29/2013 | EP2596804A2 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 05/29/2013 | EP2596803A2 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 05/29/2013 | EP2596802A1 Pharmaceutical composition for treatment of allergic reactions |
| 05/29/2013 | EP2596796A1 Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures |
| 05/29/2013 | EP2596792A1 Stable solid preparations |
| 05/29/2013 | EP2596791A1 Stable solid preparations |
| 05/29/2013 | EP2596788A1 Tacrolimus-containing oil-in-water type creamy composition |
| 05/29/2013 | EP2596024A1 Anti-cd19 antibody having adcc function with improved glycosylation profile |
| 05/29/2013 | EP2595662A1 Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile |
| 05/29/2013 | EP2595661A1 Growth hormone conjugates |
| 05/29/2013 | EP2595660A2 Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| 05/29/2013 | EP2595659A1 Method, device and system for targetted cell lysis |
| 05/29/2013 | EP2595654A1 Concentrated human immunoglobulin composition |
| 05/29/2013 | EP2595648A2 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity |
| 05/29/2013 | EP2595636A2 Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
| 05/29/2013 | EP2595626A1 Combination of siloxane and active ingredient for treating dental disorder |
| 05/29/2013 | EP2595608A2 Pharmaceutical depot for 5-fluoro-2 [ [ (1s) -1- (5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile |
| 05/29/2013 | EP2595605A1 Sulforaphane stabilization |
| 05/29/2013 | EP2595604A2 METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| 05/29/2013 | EP2595603A1 Pharmaceutical composition with enhanced solubility characteristics |
| 05/29/2013 | EP2595602A2 SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY |
| 05/29/2013 | CN1525866B Treatment using neublastin polypeptides |
| 05/29/2013 | CN103124568A Conjugated polymeric material and uses thereof |
| 05/29/2013 | CN103124565A Pharmaceutical preparation for controlling water-soluble drug release |
| 05/29/2013 | CN103124564A Compositions and methods useful for stabilizing protein-containing formulations |
| 05/29/2013 | CN103124562A FGF21 analogues and derivatives |
| 05/29/2013 | CN103124556A 贴剂 Patch |
| 05/29/2013 | CN103124554A Pharmaceutical composition |
| 05/29/2013 | CN103120798A Preparation method and application of phospholipid complex with anti-oxidative stress |
| 05/29/2013 | CN103120797A Nano-drug carrier for reductive response, nano-drug particle, nano-drug particle preparation and preparation methods thereof |
| 05/29/2013 | CN103120796A Antitumor compound of dichloroacetic acid connected with alkaline antitumor drug |
| 05/29/2013 | CN103120795A Preparation targeting macrophages |
| 05/29/2013 | CN103120794A Pharmaceutic adjuvant with collaborative work and anti-tumor application thereof |
| 05/29/2013 | CN103120702A Application of gag including hydrophobic group in preparation of drug for preventing or treating epithelium |
| 05/29/2013 | CN103120701A Application of gag including hydrophobic group in preparation of drug for preventing or treating epithelium |
| 05/29/2013 | CN103120652A 间苯三酚口腔崩解片及其制备方法 Among the three phenols orally disintegrating tablets and its preparation method benzene |
| 05/29/2013 | CN103120651A Manidipine tablet |
| 05/29/2013 | CN103120650A Rupatadine fumarate tablet |
| 05/29/2013 | CN103120649A Application of salvianolic acid freeze-dried powder injection for preparing medicine for inhibiting brain neuron damage or death |
| 05/29/2013 | CN103120647A Method for preparing omeprazole sustained-release microspheres by emulsified solvent diffusion method |
| 05/29/2013 | CN103120646A Polaprezinc granules and preparation method thereof |
| 05/29/2013 | CN103120645A Irinotecan or irinotecan hydrochloride lipidosome and preparation method thereof |
| 05/29/2013 | CN103120644A Amphiphilic segmented copolymer micelle of macromolecules of biologically functional protein and preparation and application thereof |
| 05/29/2013 | CN103120641A Graphene oxide supported benazepril compound as well as preparation method and application thereof |
| 05/29/2013 | CN102755325B Cefoxitin sodium medicinal composition, powder injection and preparation method thereof |
| 05/29/2013 | CN102743351B Pantoprazole sodium freeze-dried medicinal composition and preparation method thereof |
| 05/29/2013 | CN102631680B Method of regulating microsphere drug-load rate by treating calcium alginate microspheres with sodium chloride solution |
| 05/29/2013 | CN102631330B Lansoprazole vesicle type phospholipid gel slow release solid preparation |
| 05/29/2013 | CN102626392B Solid preparation of doxycycline ambroxol medicine compound |
| 05/29/2013 | CN102626390B Gastrodin multiphase liposome injection |
| 05/29/2013 | CN102626389B Ornidazole liposome injection |
| 05/29/2013 | CN102626388B Liposome solid preparation of ozagrel |
| 05/29/2013 | CN102626381B Vesicular phospholipid gel injection of latamoxef sodium |
| 05/29/2013 | CN102614182B Solid preparation of compound ammonia phenol renin medicine composition liposome |
| 05/29/2013 | CN102600173B Amlodipine/benazepril medicament composition liposome solid preparation |
| 05/29/2013 | CN102516388B Anthropogenic LMP1 (latent membrane protein1) extracellular regional antibody for nasopharyngeal carcinoma and application thereof |
| 05/29/2013 | CN102485218B Clopidogrel hydrogen sulfate tablet and preparation method thereof |
| 05/29/2013 | CN102429879B Ambroxol hydrochloride liposome injection |
| 05/29/2013 | CN102423293B Microemulsion gel preparation of oxiconazole nitrate |
| 05/29/2013 | CN102415986B Insoluble medicament solid dispersion containing phosphatide and cholate and preparation method thereof |
| 05/29/2013 | CN102406595B Floating microorganism adhesive porous hydrogel and preparation method thereof |
| 05/29/2013 | CN102370989B Medicinal composition for treating urinary system diseases |
| 05/29/2013 | CN102370987B Injection liposome entrapping antineoplastic pharmaceutical composition |
| 05/29/2013 | CN102366410B Argatroban liposome injection |
| 05/29/2013 | CN102295768B Circular polyethylene glycol containing single active functional group, and preparation method thereof |
| 05/29/2013 | CN102204887B In-situ formed acyclovir spraying agent and preparation method thereof |
| 05/29/2013 | CN102178659B Clarithromycin entericcoated tablet and preparation method thereof |
| 05/29/2013 | CN102151336B Active targeting drug conveying system for crossing blood brain barrier through mediation of acetylcholine receptor |
| 05/29/2013 | CN102127211B Biomass polyester |
| 05/29/2013 | CN102112157B Conjugated proteins with prolonged in vivo efficacy |
| 05/29/2013 | CN102038644B Lutein water-soluble powder and preparation process thereof |
| 05/29/2013 | CN102026664B Composition for stabilizing Beta-blocker, and transdermally absorbable preparation comprising the composition |
| 05/29/2013 | CN101925355B Fentanyl-containing patch for external use |
| 05/29/2013 | CN101883557B Novel thermosensitive liposomes containing therapeutic agents |
| 05/29/2013 | CN101883556B Transdermal delivery system for hormones and steroids |
| 05/29/2013 | CN101669924B 贴剂和贴剂制剂 Patch and patch preparation |
| 05/29/2013 | CN101646464B Oligomer-opioid agonist conjugates |
| 05/29/2013 | CN101594780B Agents for controlling parasites on animals |
| 05/29/2013 | CN101557720B Active ingredient delivery system with an amorphous metal salt as carrier |
| 05/29/2013 | CN101502656B Composition for eliminating bitter taste of soluble and stable macrolides medicament |
| 05/29/2013 | CN101287443B Pulse releasing system controlled by pH, preparation method and application thereof |
| 05/29/2013 | CN101225424B Single-glucopyranoside of cyclomembranousol, preparation method, medicament combination and uses thereof |
| 05/29/2013 | CN101157612B Organic acid menthol derivative and transdermal drug delivery preparation having the same |
| 05/28/2013 | US8450470 Use to faciliate drug delivery of other drugs, or treat glycosaminoglycan associated pathologies, such as scarring, spinal cord injury, glaucoma, and cosmetic treatments |
| 05/28/2013 | US8450459 IL-21 derivatives and variants |
| 05/28/2013 | US8450390 Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof |
| 05/28/2013 | US8450380 Method for implementing active ingredients in order to protect them and optimize their delivery method |
| 05/28/2013 | US8450339 Compositions for treatment of common cold |
| 05/28/2013 | US8450280 Activation of peptide prodrugs by hK2 |
| 05/28/2013 | US8450097 Protein-proteophore complexes |
| 05/28/2013 | US8449884 Clotting factor-fc chimeric proteins to treat hemophilia |
| 05/28/2013 | US8449872 Polymer conjugates of nesiritide peptides |
| 05/28/2013 | CA2731995C Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| 05/28/2013 | CA2685447C Pharmaceutical composition |
| 05/28/2013 | CA2650698C Copolyvidone-containing preparation |
| 05/28/2013 | CA2644552C Peptide lipid-containing carrier and method for introducing compound into cells using same |